<DOC>
	<DOCNO>NCT01818284</DOCNO>
	<brief_summary>The goal clinical research study learn treat stem cell donor filgrastim ( G-CSF ) plerixafor ( MozobilÂ® ) cause produce high number blood stem cell filgrastim . Researchers also want learn give drug help donor produce enough stem cell 1 apheresis procedure need perform . Researchers study use drug lower risk stem cell transplant recipient develop severe form graft-versus-host disease ( GVHD ) . GVHD condition transplant tissue ( blood stem cell ) attack tissue recipient 's body . The safety effectiveness drug combination also study . Filgrastim plerixafor design help move `` mobilize '' stem cell bone marrow blood .</brief_summary>
	<brief_title>Plerixafor Stem Cell Mobilization Normal Donors</brief_title>
	<detailed_description>Stem Cell Transplant : You receive blood stem cell donor study . You sign separate inform consent transplant procedure . Follow-Up Visits : About 1 , 3 , 6 month transplant , extra sample bone marrow ( 2 teaspoon ) collect time standard care bone marrow aspiration/biopsy procedure . This bone marrow sample test find well donated stem cell accept body . However , separate bone marrow aspiration/biopsy collect bone marrow test . When return clinic 6 , 9 , 12 month routine transplant follow-up visit , study staff try get information health status clinic note medical record . If possible , may receive phone call study staff check health status . These call last 10 minute . Length Treatment : You study 1 year transplant ( include follow-up contact phone , need ) . You may take study early able follow study direction decide leave study . This investigational study . Filgrastim FDA approve use stem cell collection . Plerixafor FDA approve use patient multiple myeloma non-Hodgkin 's lymphoma . Up 30 donor recipient pair take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Donor eligibility : Age &gt; /= 10 year . 2 . Donor eligibility : Related donor meet standard eligibility criterion willing participate study . 3 . Donor eligibility : Able provide inform consent . 4 . Recipient Eligibility : Patients schedule undergo allogeneic related transplant whose donor consent participate study . 5 . Recipient Eligibility : Able provide inform consent . 1 ) Donors anticoagulation antiplatelet agent eligible .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Normal allogeneic donor</keyword>
	<keyword>Stem cell mobilization</keyword>
	<keyword>peripheral blood progenitor cell</keyword>
	<keyword>PBPC</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>HSCT</keyword>
	<keyword>Donating blood stem cell</keyword>
	<keyword>C-CSF</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Mobozil</keyword>
	<keyword>Apheresis</keyword>
</DOC>